Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes

References

• BaileyCJTurnerRCMetforminN Engl J Med199633457498569826
   PubMed Web of Science ®Google Scholar
• BalletshoferBMRittigKEnderleMDEndothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistanceCirculation20001011780410769277
   PubMed Web of Science ®Google Scholar
• BasuAJensenMDMcCannFEffects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetesDiabetes Care2006295101416505497
   PubMed Web of Science ®Google Scholar
• BergholmRTiikkainenMVehkavaaraSLowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetesDiabetes Care20032616677212766091
   PubMed Web of Science ®Google Scholar
• BetteridgeDJVergesBLong-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetesDiabetologia20054824778116283239
   PubMed Web of Science ®Google Scholar
• BruemmerDBlaschkeFLawRENew targets for PPARgamma in the vessel wall: implications for restenosisInt J Obes (Lond)200529Suppl 1S263015711579
   PubMedGoogle Scholar
• CaballeroAEMetabolic and vascular abnormalities in subjects at risk for type 2 diabetes: the early start of a dangerous situationArch Med Res200536241915925014
   PubMed Web of Science ®Google Scholar
• CaldwellSHArgoCKAl-OsaimiAMTherapy of NAFLD: insulin sensitizing agentsJ Clin Gastroenterol200640S61616540770
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetologia2005481093415889234
   PubMed Web of Science ®Google Scholar
• ChenKLiFLiJInduction of leptin resistance through direct interaction of C-reactive protein with leptinNat Med2006124253216582918
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDefronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med2004164209710415505122
   PubMed Web of Science ®Google Scholar
• DaileyGE3rdNoorMAParkJSGlycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trialAm J Med2004116223914969649
   PubMed Web of Science ®Google Scholar
• DeFronzoRAPathogenesis of type 2 diabetes mellitusMed Clin North Am200488787835ix15308380
   PubMed Web of Science ®Google Scholar
• DeFronzoRAGoldbergMAgusZSThe effects of glucose and insulin on renal electrolyte transportJ Clin Invest1976588390932211
   PubMed Web of Science ®Google Scholar
• DeFronzoRAGunnarssonRBjorkmanOEffects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitusJ Clin Invest198576149553894418
   PubMed Web of Science ®Google Scholar
• DelerivePMartin-NizardFChinettiGPeroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathwayCirc Res19998539440210473669
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract2005a6951315955382
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAVLong-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trialClin Ther2005b2713839116291411
   PubMed Web of Science ®Google Scholar
• Di CiccoRAAllenACarrARosiglitazone does not alter the pharmacokinetics of metforminJ Clin Pharmacol2000401280511075314
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• EinhornDRendellMRosenzweigJPioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupClin Ther200022139540911192132
   PubMed Web of Science ®Google Scholar
• FonsecaVRosenstockJPatwardhanREffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trialJAMA2000283169570210755495
   PubMed Web of Science ®Google Scholar
• FryerLGParbu-PatelACarlingDThe Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathwaysJ Biol Chem2002277252263211994296
   PubMed Web of Science ®Google Scholar
• GastaldelliAMiyazakiYPettitiMMetabolic effects of visceral fat accumulation in type 2 diabetesJ Clin Endocrinol Metab200287509810312414878
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• GinsbergHKimmerlingGOlefskyJMDemonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemiaJ Clin Invest197555454611117064
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineAvandamet: summary of product characteristics [online]2007 URL: http://us.gsk.com/products/assets/us_avandamet.pdf
   Google Scholar
• Gomez-PerezFJFanghanel-SalmonGAntonio BarbosaJEfficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetesDiabetes Metab Res Rev2002181273411994904
   PubMed Web of Science ®Google Scholar
• GrannerDKO’BrienRMMolecular physiology and genetics of NIDDM. Importance of metabolic stagingDiabetes Care199215369951559407
   PubMed Web of Science ®Google Scholar
• HaffnerSMLehtoSRonnemaaTMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med1998339229349673301
   PubMed Web of Science ®Google Scholar
• HaffnerSMSternMPHazudaHPCardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?JAMA1990263289382338751
   PubMed Web of Science ®Google Scholar
• HardieDGCarlingDCarlsonMThe AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell?Annu Rev Biochem199867821559759505
   PubMed Web of Science ®Google Scholar
• HawleySADavisonMWoodsACharacterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinaseJ Biol Chem199627127879878910387
   PubMed Web of Science ®Google Scholar
• HowardBVRodriguezBLBennettPHPrevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiologyCirculation2002105e132711994263
   PubMed Web of Science ®Google Scholar
• HundalRSKrssakMDufourSMechanism by which metformin reduces glucose production in type 2 diabetesDiabetes2000492063911118008
   PubMed Web of Science ®Google Scholar
• InzucchiSEMaggsDGSpollettGREfficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitusN Engl J Med1998338867729516221
   PubMed Web of Science ®Google Scholar
• KatoKSatohHEndoYThiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial functionBiochem Biophys Res Commun1999258431510329404
   PubMed Web of Science ®Google Scholar
• KendallDMRubinCJMohideenPImprovement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative studyDiabetes Care20062910162316644631
   PubMed Web of Science ®Google Scholar
• KerstenSDesvergneBWahliWRoles of PPARs in health and diseaseNature2000405421410839530
   PubMed Web of Science ®Google Scholar
• KirpichnikovDMcFarlaneSISowersJRMetformin: an updateAnn Intern Med2002137253312093242
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• LargeVBeylotMModifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metforminDiabetes1999481251710342812
   PubMed Web of Science ®Google Scholar
• LeeYHiroseHOhnedaMBeta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationshipsProc Natl Acad Sci USA19949110878827971976
   PubMed Web of Science ®Google Scholar
• LilliojaSMottDMHowardBVImpaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima IndiansN Engl J Med19883181217253283552
   PubMed Web of Science ®Google Scholar
• MagnussonIRothmanDLKatzLDIncreased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance studyJ Clin Invest199290132371401068
   PubMed Web of Science ®Google Scholar
• MatthewsDRCharbonnelBHHanefeldMLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes Metab Res Rev2005211677415386821
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSBEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialJAMA200629625728117101640
   PubMed Web of Science ®Google Scholar
• MeigsJBLarsonMGD’AgostinoRBCoronary artery calcification in type 2 diabetes and insulin resistance: the framingham offspring studyDiabetes Care2002251313912145227
   PubMed Web of Science ®Google Scholar
• MeigsJBMittlemanMANathanDMHyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring StudyJAMA2000283221810634338
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMEffect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab20028727849112050251
   PubMed Web of Science ®Google Scholar
• MollerDEPotential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetesTrends Endocrinol Metab200011212710878750
   PubMed Web of Science ®Google Scholar
• NataliABaldewegSToschiEVascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetesDiabetes Care20042713495715161787
   PubMed Web of Science ®Google Scholar
• NolanJJLudvikBBeerdsenPImprovement in glucose tolerance and insulin resistance in obese subjects treated with troglitazoneN Engl J Med19943311188937935656
   PubMed Web of Science ®Google Scholar
• OvalleFBellDSEffect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetesDiabetes Care2004272585915504990
   PubMed Web of Science ®Google Scholar
• PerezAKhanMJohnsonTPioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetesDiab Vasc Dis Res20041445016305056
   PubMedGoogle Scholar
• PerrielloGMisericordiaPVolpiEAcute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose productionDiabetes19944392088013758
   PubMed Web of Science ®Google Scholar
• PischonTGirmanCJHotamisligilGSPlasma adiponectin levels and risk of myocardial infarction in menJAMA20042911730715082700
   PubMed Web of Science ®Google Scholar
• PolonskyKSSturisJBellGISeminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus – a genetically programmed failure of the beta cell to compensate for insulin resistanceN Engl J Med1996334777838592553
   PubMed Web of Science ®Google Scholar
• RoeMWWorleyJF3rdTokuyamaYNIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activityAm J Physiol1996270E133408772485
   PubMedGoogle Scholar
• RosenstockJSugimotoDStrangePTriple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patientsDiabetes Care200629554916505505
   PubMed Web of Science ®Google Scholar
• RossettiLDeFronzoRAGherziREffect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlationsMetabolism199039425352157941
   PubMed Web of Science ®Google Scholar
• SaadMFKnowlerWCPettittDJThe natural history of impaired glucose tolerance in the Pima IndiansN Engl J Med1988319150063054559
   PubMed Web of Science ®Google Scholar
• SaadMFKnowlerWCPettittDJSequential changes in serum insulin concentration during development of non-insulin-dependent diabetesLancet19891135692567374
   PubMed Web of Science ®Google Scholar
• SamahaFFSzaparyPOIqbalNEffects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndromeArterioscler Thromb Vasc Biol2006266243016357312
   PubMed Web of Science ®Google Scholar
• Takeda Pharmaceuticals Actosplus MetPrescribing information [online] Accessed 25 July 2007. URL: http://www.actos.com/actos/prescribinginfo.aspx
   Google Scholar
• UKPDSEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) GroupLancet1998352854659742977
   PubMed Web of Science ®Google Scholar
• UmpierrezGIssaMVlajnicAGlimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trialCurr Med Res Opin200622751916684436
   PubMed Web of Science ®Google Scholar
• UngerRHLongevity, lipotoxicity and leptin: the adipocyte defense against feasting and famineBiochimie200587576415733738
   PubMed Web of Science ®Google Scholar
• WeissmanPGoldsteinBJRosenstockJEffects of rosiglitazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE StudyCurr Med Res Opin20052120293516368054
   PubMed Web of Science ®Google Scholar
• WilsonPWD’ AgostinoRBPariseHMetabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitusCirculation200511230667216275870
   PubMed Web of Science ®Google Scholar
• WilsonPWD’ AgostinoRBSullivanLOverweight and obesity as determinants of cardiovascular risk: the Framingham experienceArch Intern Med200216218677212196085
   PubMed Web of Science ®Google Scholar
• XiangAHPetersRKKjosSLEffect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetesDiabetes2006555172216443789
   PubMed Web of Science ®Google Scholar
• YeJMDzamkoNCleasbyMEDirect demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metforminDiabetologia20044713061315232684
   PubMed Web of Science ®Google Scholar
• YeJMFrangioudakisGIglesiasMAPrior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liverEndocrinology200214345273512446579
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHThiazolidinedionesN Engl J Med200435111061815356308
   PubMed Web of Science ®Google Scholar